Evinacumab in homozygous familial hypercholesterolaemia: long-term safety and efficacy

Abstract

In this large cohort of patients with HoFH, evinacumab was generally well tolerated and markedly decreased LDL-C irrespective of age and sex. Moreover, the efficacy and safety of evinacumab was sustained over the long term.